The disclosure is directed to novel personalized therapies and methods for treating ankylosing spondylitis (AS). Specifically, this disclosure relates to methods of treating a patient having AS by selectively administering an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab, to the AS patient on the basis of that patient being predisposed to have a favorable response to treatment with the IL-17 antagonist. Also disclosed herein are diagnostic methods and transmittable forms of information useful in predicting the likelihood that a patient having AS will respond to treatment with an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab.本發明係關於用於治療關節黏連性脊椎炎(AS)之新穎個人化療法及方法。特定言之,本發明係關於治療患有AS之患者的方法,其藉由基於該患者傾向於對接受IL-17拮抗劑治療具有有利反應而向該AS患者選擇性投與該IL-17拮抗劑,例如IL-17抗體,諸如塞庫金單抗(secukinumab)。本文中亦揭示適用於預測患有AS之患者將對接受IL-17拮抗劑(例如IL-17抗體,諸如塞庫金單抗)治療有反應之可能性的診斷方法及可傳送資訊形式。